Novartis CD20 Antibody ofatumumab reaches major end in Phase 3 clinical trial streats on RMS patients

MS is a chronic disease of the central nervous system (CNS), which disrupts the normal function of the brain, optic nerve and spinal cord through inflammation and tissue damageNovartis(http:// announcedthat its humanized CD20 antibody of oftatumab, which reached its main endpoint in theof clinical(http:// for patients with recurrent multiple sclerosis (RMS), performed better than another common drug used to treat multiple sclerosis (MS)Novartis is expected to file a regulatory application with theFDA(http://by the end of the year, and if approved, ofumab is expected to become the first home-based treatment for RMS."About Ofatumab
Ofatumumab is a fully human-derived CD20 antibodyBy binding to CD20 on the surface of B lymphocytes, it is able to remove B cells from the blood, which play an important role in stimulating autoimmune responses in MS patientsOfatumab allows patients to be given medicine once a month through subcutaneous injections at homeNot only for the control of the disease provides convenience, but also can better target the B cells in the lymphatic rhythm, reducing the damage to B cells in the spleen Previously, ofumumab had been approved by the FDA as a leukemia treatment related research
 A total of 1,882 MS patients in the participated in the 30-month ASCLEPIOS trial The trial consisted of two double-blind, randomized trials, which were a head-to-head comparison trial, comparing the safety and efficacy of the treatment of MS adult patients with teriflunomide 　　The results showed that the main clinical endpoint struck at reducing the annual recurrence rate (ARR) of MS compared with the active control group Its critical secondary endpoints for delaying the progression of the disease have also been met 　　In terms of safety
Ofatumab also demonstrates good safety and continuous efficacy